1,368 results match your criteria Melanoma Iris


Therapy of uveal melanoma A Review.

Cesk Slov Oftalmol 2020 ;1(Ahead of print):1-13

The aim of intraocular melanoma therapy is to achieve local tumor control, reduce the risk of metastasis development, preserve the eyeball and possibly the visual function of the eye. The choice of therapeutic approach requires a comprehensive view and individual approach to each patient with uveal melanoma. Factors considered include local finding (location, tumor size and shape, tumor activity, central visual acuity, intraocular complications), age and the patients overall physical and psychological condition, as well as the patients wishes. Read More

View Article and Full-Text PDF

Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-Part I: MR imaging with pathologic correlation and technical considerations.

Insights Imaging 2021 Jun 3;12(1):66. Epub 2021 Jun 3.

Department of Medical Surgical Sciences and Advanced Technologies "G.F. Ingrassia" - Radiology I Unit, University Hospital Policlinico "G. Rodolico-San Marco", Via Santa Sofia 78, 95123, Catania, Italy.

Uveal melanoma is a malignant neoplasm that derives from pigmented melanocytes of the uvea and involves, in order of decreasing prevalence, the choroid, ciliary body and iris. Its prognosis is related to histopathologic and genetic features, tumor size and location, extraocular extension. The diagnosis is fundamentally based on clinical evaluation (ophthalmoscopy, biomicroscopy) and ultrasonography. Read More

View Article and Full-Text PDF

Pigment Epithelium Macroadenoma Mimicking Iris or Ciliary Body Melanoma.

J Ophthalmic Vis Res 2021 Apr-Jun;16(2):306-318. Epub 2021 Apr 29.

Servicio de Oftalmología, Unidad de Tumores Intraoculares del Adulto, Hospital Clínico Universitario de Valladolid, Spain.

View Article and Full-Text PDF

Plaque brachytherapy in iris and iridociliary melanoma: a systematic review of efficacy and complications.

J Contemp Brachytherapy 2021 Feb 18;13(1):46-50. Epub 2021 Feb 18.

Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Purpose: To evaluate the efficacy and vision-threatening complication rate of plaque brachytherapy with iodine-125 (I), palladium-103 (Pd), and ruthenium-106 (Ru) for treatment of iris and iridociliary melanoma.

Material And Methods: A literature review was done based on results yielded from searching PubMed, Embase, and Cochrane database, using following key words: iris melanoma, iridociliary melanoma, brachytherapy, iodine-125 brachytherapy, palladium-103 brachytherapy, and ruthenium-106 brachytherapy. Initially, relationships between mean radiation dose to apex and local recurrence and complication rate were analyzed, and then, a comparison was performed between I, Pd, and Ru studies. Read More

View Article and Full-Text PDF
February 2021

Shielded high dose rate ocular brachytherapy using Yb-169.

Phys Med Biol 2021 Jun 7;66(12). Epub 2021 Jun 7.

Worcester Polytechnic Institute, Worcester, MA 01609, United States of America.

We propose an approach for treating ocular melanoma using a new type of brachytherapy treatment device. This device couples Yb-169, a middle-energy high dose rate (HDR) brachytherapy source, with a gold shielded ring applicator to better conform radiation exposures to the tumor. In this study, we computationally test the dosimetric output of our proposed shielded ring applicator design using MCNP6 and validate it against an I-125 COMS plaque. Read More

View Article and Full-Text PDF

Ocular safety profile of BRAF and MEK inhibitors: data from the World Health Organization Pharmacovigilance Database.

Ophthalmology 2021 May 14. Epub 2021 May 14.

Service de Médecine Interne, Centre de Référence des maladies auto-immunes systémiques rares d'Ile de France, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; Université de Paris, F-75006, Paris, France. Electronic address:

Purpose: BRAF (BRAFi) and MEK (MEKi) inhibitors significantly improved metastatic melanoma prognosis. Ocular adverse effects (OAEs) represent an uncommon but disabling toxicity of these drugs. We aimed to characterize the ocular safety profile of BRAFi and/or MEKi and to detect possible safety signals. Read More

View Article and Full-Text PDF

Partial lamellar sclerouvectomy surgery for anteriorly located uveal tumour resection: a 20-year experience.

Eye (Lond) 2021 May 3. Epub 2021 May 3.

Departmant of Pathology, Ankara University Faculty of Medicine, Ankara, Turkey.

Objectives: To investigate the results of partial lamellar sclerouvectomy (PLSU) for anteriorly located uveal tumours.

Methods: We reviewed the tumour features, histopathologic findings, complications, visual acuity outcomes, eye preservation, metastasis, and mortality data of 56 cases with uveal tumours who underwent PLSU between February 1999 and February 2019.

Results: The mean largest tumour base diameters were 5. Read More

View Article and Full-Text PDF

Choroidal melanoma in phakomatosis pigmentovascularis with overlapping Sturge-Weber syndrome and Klippel-Trenaunay syndrome.

Retin Cases Brief Rep 2021 Apr 16. Epub 2021 Apr 16.

From the Ocular Oncology Service, Department of Ophthalmology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Purpose: T' trunk, along with hemi-hypertrophy of the left side of the face and left upper limb, presented for evaluation of an intraocular mass of the left eye (OS). Anterior examination OS showed diffuse episcleral and iris melanocytosis. Fundus examination OS showed diffuse choroidal melanocytosis as well as an elevated choroidal lesion. Read More

View Article and Full-Text PDF

Relief of symptomatic pseudo-polycoria due to iris biopsy using a daily contact lens.

Am J Ophthalmol Case Rep 2021 Jun 1;22:101084. Epub 2021 Apr 1.

Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, NY, USA.

Purpose: To report a case of pseudo-polycoria from iris biopsy managed by a daily disposable prosthetic colored hydrogel lens.

Observations: A 55-year-old- Caucasian female presented with complaints of photophobia in her right eye, that was exacerbated when going from a dark to light environment. Her past ocular history included a diagnosis by another outside physician of presumed multifocal iris melanoma in the right eye, followed by an iris biopsy performed one month later. Read More

View Article and Full-Text PDF

Regression of posterior uveal melanoma following iodine-125 plaque radiotherapy based on pre-treatment tumor apical height.

J Contemp Brachytherapy 2021 Apr 14;13(2):117-125. Epub 2021 Apr 14.

Intraocular Tumors Unit, Valladolid University Hospital, Valladolid, Spain.

Purpose: The aim of this study was to analyze regression rates and local control of uveal melanoma patients treated with iodine-125 I) brachytherapy based on initial tumor apical height.

Material And Methods: Patients treated in a single institution from January 1, 1996 to 2019 with I plaques (ROPES and COMS) for uveal melanoma were included in this study. Patients treated with brachytherapy for iris and those treated with transpupillary thermotherapy prior to brachytherapy were excluded. Read More

View Article and Full-Text PDF

Rapid growth of primary uveal melanoma following intravitreal bevacizumab injection: a case report and review of the literature.

Digit J Ophthalmol 2021 Feb 3;26(3):27-30. Epub 2020 Jul 3.

Department of Ophthalmology and Visual Sciences, University of Alberta, Edmonton, Alberta, Canada.

Uveal melanoma size is a significant predictor of tumor metastasis. Although the relationship between antivascular endothelial growth factors (VEGF) and uveal melanoma growth has been studied, results are paradoxical, and the relationship remains controversial. We report the case of a 65-year-old man who presented with elevated intraocular pressure in his right eye, neovascularization of his iris, and significant corneal edema, which obscured the view of the angle. Read More

View Article and Full-Text PDF
February 2021

Concurrence of peripunctal nevus and uveal melanoma with scleral pigment dispersion presenting as phthisis bulbi.

BMJ Case Rep 2021 Apr 16;14(4). Epub 2021 Apr 16.

Ocular Oncology, The Operation Eyesight Univeraal Institute for Eye Cancer, LV Prasad Eye Institute, Hyderabad, Telangana, India

This case report demostrates an unusual occurence of peripunctal nevus and uveal melanoma, in which the clinical diganosis of uveal melanoma was masked by the atypical presentation as phthisis bulbi. Nevertheless, peculiar scleral pigment hinted at a possible intraocular tumour. The importance of meticulous clinical examination in assessment of ocular and periocular pigmented lesions is demonstrated. Read More

View Article and Full-Text PDF

Sunlamp use is a risk factor for uveal melanoma: a meta-analysis.

Can J Ophthalmol 2021 Apr 8. Epub 2021 Apr 8.

Department of Surgery, Faculty of Medicine and Dentistry, University of Calgary, Calgary, Alb.

Objective: Advancements in the treatment of uveal melanoma have not improved survival; therefore, identifying modifiable risk factors is critical to improving outcomes. This study aims to investigate the association between sunlamp use and the development of uveal melanoma.

Design: This study is designed as a meta-analysis. Read More

View Article and Full-Text PDF

Sunglasses to hide behind may also prevent melanoma of the eyes.

Br J Cancer 2021 Apr 6. Epub 2021 Apr 6.

Molecular Oncology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, SK10 4TG, UK.

In 1967, Sandy Posey pronounced that sunglasses are essential beachwear ( https://www.youtube.com/watch?v=4HVBEb-GA1Y ). Read More

View Article and Full-Text PDF

Locally Invasive Diffuse Iris Ring Melanoma Presenting as Unilateral Severe Glaucoma: Case Report and Review of Molecular Genetics.

Case Rep Oncol 2021 Jan-Apr;14(1):403-410. Epub 2021 Mar 11.

Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas, USA.

We report the clinical history and histopathological findings in a case of diffuse iris ring melanoma (DIM) and review the most recent literature and modern molecular genetics of this entity. An 85-year-old Hispanic man presented with severe unilateral glaucoma, managed at an outside institution for 2 years prior to presentation. Diffuse pigmentation was noted in the angle, on the intraocular lens implant, and in the vitreous without clear demonstration of a mass on ultrasound biomicroscopy. Read More

View Article and Full-Text PDF

Robotic assisted CyberKnife radiosurgery for the treatment of iris melanoma.

Sci Rep 2021 Mar 11;11(1):5685. Epub 2021 Mar 11.

Department of Ophthalmology, Ludwig-Maximilians University Munich, Mathildenstr. 8, 80336, Munich, Germany.

Iris melanoma is a rare form of uveal melanoma with potential metastic spread. Treatment options include surgical resection, enucleation or irradiation. We analysed visual outcome, complication appearance and management in eight patients with iris melanoma following robotic-assisted CyberKnife treatment. Read More

View Article and Full-Text PDF

Iris melanoma with neovascularization in sector melanocytosis controlled with I plaque radiotherapy and bevacizumab.

J Fr Ophtalmol 2021 May 17;44(5):738-739. Epub 2021 Feb 17.

Ocular Oncology Service, Wills Eye Hospital, Thomas-Jefferson University, 840, Walnut Street, 14th Floor, 19107 Philadelphia, PA, United States. Electronic address:

View Article and Full-Text PDF

Clinicopathologic analysis of 32 ciliary body tumors.

Jpn J Ophthalmol 2021 Mar 19;65(2):237-249. Epub 2021 Feb 19.

Department of Ophthalmology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.

Purpose: To describe the demographic profile, clinical and histopathologic features, and treatment of ciliary body tumors.

Study Design: Retrospective, observational case series.

Methods: Thirty-two patients (32 eyes) with ciliary body tumors diagnosed histopathologically at Tokyo Medical University Hospital between 1994 and 2017 were retrospectively reviewed. Read More

View Article and Full-Text PDF

Iris extramedullary hematopoiesis in choroidal melanoma.

Saudi J Ophthalmol 2020 Apr-Jun;34(2):82-84. Epub 2020 Dec 28.

Ocular Oncology Service, Moorfields Eye Hospital, Helsinki, Finland.

Purpose: Extramedullary hematopoiesis (EMH) usually occurs in patients with loss of bone marrow hematopoietic function, and in a vast majority of cases, it involves the liver, the spleen, or the lymph nodes. We report EMH in the iris of patients enucleated for choroidal melanoma (CM).

Methods: We report a series of three patients with CM, two treated with primary enucleation and one with secondary enucleation. Read More

View Article and Full-Text PDF
December 2020

Long-term results of visual function in posterior uveal melanoma patients treated with I125 episcleral brachytherapy in a Spanish referral Ocular Oncology Unit.

Arq Bras Oftalmol 2021 Feb 3. Epub 2021 Feb 3.

Statistics Unit, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.

Purposes: We analyzed patient, tumor and dosimetric characteristics of subjects in a Spanish population diagnosed with uveal melanoma treated with iodine 125 (I125) episcleral brachytherapy, who presented with post-treatment loss of useful visual acuity and global evolution of visual acuity.

Methods: A single historic observational cohort study was undertaken. Patients with uveal melanoma were recruited between September 1995 and June 2015. Read More

View Article and Full-Text PDF
February 2021

Genetic drivers of non-cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape.

Exp Dermatol 2021 Jan 17. Epub 2021 Jan 17.

Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

Non-cutaneous melanomas most frequently involve the uveal tract and mucosal membranes, including the conjunctiva. In contrast to cutaneous melanoma, they often present at an advanced clinical stage, are associated with worse clinical outcomes and show poorer responses to immunotherapy. The mutational load within most non-cutaneous melanomas reflects their lower ultraviolet light (UV) exposure. Read More

View Article and Full-Text PDF
January 2021

Patients presenting with metastases: stage IV uveal melanoma, an international study.

Br J Ophthalmol 2021 Jan 15. Epub 2021 Jan 15.

Department of Ophthalmic Oncology, National Cancer Center Hospital, Tokyo, Japan.

Objective: To analyse ocular and systemic findings of patients presenting with systemic metastasis.

Methods And Analysis: It is an international, multicentre, internet-enabled, registry-based retrospective data analysis. Patients were diagnosed between 2001 and 2011. Read More

View Article and Full-Text PDF
January 2021

Clinical Characteristics of UM and Association of Metastasis of Uveal Melanoma with Congenital Oculocutaneous Melanosis in Asian Patients: Analysis of 1151 Consecutive Eyes.

Ophthalmol Retina 2021 Jan 12. Epub 2021 Jan 12.

Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Medical Artificial Intelligence Research and Verification Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Electronic address:

Purpose: To analyze the clinical characteristics of uveal melanoma (UM) and evaluate the relationship of congenital oculocutaneous melanosis (OCM) to the prognosis of Asian patients with UM.

Design: Retrospective cohort study.

Participants: We included a total of 1151 Asian patients with UM who were managed at the Beijing Tongren Hospital from June 26, 2005, to July 27, 2020. Read More

View Article and Full-Text PDF
January 2021

[Congenital ocular melanocytosis].

Rev Med Liege 2021 Jan;76(1):2-6

Service d'Ophtalmologie, CHR Citadelle, Liège, Belgique.

Congenital oculodermal melanocytosis represents a unilateral accumulation of melanocytes in the episclera, sclera and uveal tract. Clinically, it manifests with iris heterochromia, episcleral and scleral pigmented patches, dark pigmentation of the trabecular meshwork and the fundus. This congenital disorder is a predisposing factor for uveal melanoma and chronic glaucoma. Read More

View Article and Full-Text PDF
January 2021

Genetics of Ocular Melanoma: Insights into Genetics, Inheritance and Testing.

Int J Mol Sci 2020 Dec 30;22(1). Epub 2020 Dec 30.

Department of Ophthalmology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands.

Ocular melanoma consists of posterior uveal melanoma, iris melanoma and conjunctival melanoma. These malignancies derive from melanocytes in the uveal tract or conjunctiva. The genetic profiles of these different entities differ from each other. Read More

View Article and Full-Text PDF
December 2020

Estimating Cured Fractions of Uveal Melanoma.

JAMA Ophthalmol 2021 02;139(2):174-181

Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

Importance: The extent to which uveal melanoma is cured by ocular therapy is not known.

Objective: To estimate cured fractions (CF) of uveal melanoma using combination of institutional and Surveillance, Epidemiology, and End Results (SEER) data.

Design, Setting, And Participants: Integrative analysis of 42 years of SEER data (1975-2016) with 25 years (1993-2018) of complementary institutional data. Read More

View Article and Full-Text PDF
February 2021

Proton beam irradiation of uveal melanoma involving the iris, ciliary body and anterior choroid without surgical localisation (light field).

Br J Ophthalmol 2020 Dec 21. Epub 2020 Dec 21.

Retina Service, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA

Aims: To assess treatment outcomes after proton beam irradiation (PBI) without surgical localisation of uveal melanomas involving the iris, ciliary body and anterior choroid.

Methods: Retrospective chart review of 125 patients evaluated at Massachusetts Eye and Ear and treated with PBI using a light field set-up without localisation surgery between November 1975 and April 2017. The tumours were characterised as follows: iris (n=18, 14. Read More

View Article and Full-Text PDF
December 2020

Sclerouvectomy plus intraoperative ophthalmic brachytherapy for iris-ciliary body melanomas.

Surg Oncol 2021 Mar 11;36:113-114. Epub 2020 Dec 11.

Retina Unit, Department of Ophthalmology, Virgen Macarena University Hospital, Seville, Spain; RETICS OftaRed, Institute of Health Carlos III, Madrid, Spain.

Background: Partial lamellar sclerouvectomy was designed more than 30 years ago by Jerry and Carol Shields, in order to remove melanomas that involved the ciliary body and/or the choroid, while leaving intact the outer portion of the sclera and the overlying sensory retina [1].

Methods: We present two cases of iris-ciliary body melanoma with different size. The performed surgery was a partial lamellar sclerouvectomy plus iridectomy, complemented by intraoperative juxtalimbar ruthenium-106 brachytherapy. Read More

View Article and Full-Text PDF

The Macro-Autophagy-Related Protein Beclin-1 Immunohistochemical Expression Correlates With Tumor Cell Type and Clinical Behavior of Uveal Melanoma.

Front Oncol 2020 20;10:589849. Epub 2020 Nov 20.

Section of Anatomic Pathology, Department Gian Filippo Ingrassia, University of Catania, Catania, Italy.

Uveal melanoma, in spite of its rarity, represents the most common primitive intraocular malignant neoplasm of the adults; it affects choroid, ciliary bodied and iris and remains clinically silent for a long time, being accidentally discovered by routine ophthalmic exams. Prognosis of uveal melanoma is poor and frequently characterized by liver metastases, within 10-15 years from diagnosis. Autophagy is a multi-step catabolic process by which cells remove damaged organelles and proteins and recycle nutrients. Read More

View Article and Full-Text PDF
November 2020

Doctor reported outcomes: Real-world data from a tertiary eye cancer center.

Indian J Ophthalmol 2021 Jan;69(1):135-139

Department of Ocular Tumor and Orbital Disease, The New York Eye Cancer Center, New York, NY, USA.

Purpose: To provide real-world data on the world-wide-web for patient and doctor awareness.

Methods: From December 2017 to January 2020, consecutive patients with choroidal melanoma (CM), iris ciliary body melanoma (ICM), and ocular surface squamous carcinoma (OSSC) had specific outcomes recorded at each return visit. Each result was anonymized, entered in an online portal, and sent to a unique software program where it was used to create real-world data of number of patients, mean vision, local tumor control, eye salvage, systemic metastases, and length of follow-up for our eye cancer center. Read More

View Article and Full-Text PDF
January 2021